PRP

PRP is a proprietary proenzyme-based cancer therapy developed by Propanc Biopharma. It consists of a synergistic 1:6 ratio of two pancreatic proenzymes, trypsinogen and chymotrypsinogen, derived from bovine sources. Administered intravenously, PRP is designed to target cancer stem cells and prevent tumor recurrence and metastasis in solid tumors, specifically pancreatic, ovarian, and colorectal cancers. Its mechanism of action involves the reversal of epithelial-mesenchymal transition (EMT), promotion of cancer cell differentiation, inhibition of tumor angiogenesis, and modulation of key signaling pathways including TGFβ, Hippo, Wnt, and Notch. The therapy has received FDA Orphan Drug Designation for pancreatic cancer and is currently in Phase II development.

Other names

trypsinogen + chymotrypsinogenproenzyme formulation